Skip to content
MarketScale
‹ Back to IndustriesHealthcare

NIH Puts New Clinical Trial Guidelines Into Effect

Researchers requesting funding for clinical trials must determine if their research meets new criteria set by new NIH guidelines. The new guidelines breaks from the traditional understanding to also  include both basic biomedical research and basic social and behavioral research. The switch has caused somewhat of a controversy, with some researchers claiming that the guidelines…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Researchers requesting funding for clinical trials must determine if their research meets new criteria set by new NIH guidelines. The new guidelines breaks from the traditional understanding to also include both basic biomedical research and basic social and behavioral research.

The switch has caused somewhat of a controversy, with some researchers claiming that the guidelines are too broad, and the new policies will increase researcher burdens. In September, more than 3500 scientists signed an open letter requesting NIH to delay the policy. Researchers conducting trials are now required to register and report results on ClinicalTrials.gov, but, if researchers impacted by the change do not select a funding opportunity that supports clinical trials when they apply to NIH, their grant is subjected to be rejected without a review.

Though some clarification from NIH in recent months has quelled many of the concerns expressed, some researchers have lingering doubts. “There’s still a problem, but the problem is less dire than the original set of concerns that we had,” says cognitive psychologist Jeremy Wolfe of the Harvard University.[1]

The guidelines go into effect on January 25th.

[1]

http://www.sciencemag.org/news/2018/01/nih-s-new-clinical-trial-policy-kicks-despite-concerns-basic-behavioral-researchers

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Healthcare expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Leading with Purpose: Dr. David Foster on Faith, Healthcare Leadership, and Physician Collaboration

Dr. David Foster discusses the importance of faith in healthcare leadership and the role of physician collaboration. The conversation emphasizes how values-driven leadership can positively impact patient care. The dialogue also explores the significance of integrating personal beliefs in professional settings.

  • 01Values-driven leadership can significantly enhance patient care.
  • 02Integrating personal beliefs in professional settings can benefit healthcare leadership.
  • 03Collaboration among physicians is crucial for effective healthcare leadership.

Aug 4, 2026

Digital health VC hits $7.4B in H1 2026 as AI agents, chronic care, and workforce tools capture mega-deal capital

Digital health VC hits $7.4B in H1 2026 as AI agents, chronic care, and workforce tools capture mega-deal capital

Digital health venture funding reached $7.4B in the first half of 2026, with significant investments in AI agent platforms and chronic care tools. Mega-deals of over $100 million were a key driver of the funding surge.

  • 01Digital health VC funding hit $7.4 billion in the first half of 2026.
  • 02Mega-deals in AI agent platforms and chronic care tools exceeded $100 million.
  • 03AI, chronic care, and workforce tools dominate digital health investments.

Aug 4, 2026

Pharma M&A surges on a single day: KKR's $5.7B Integer deal, Curium's $8B Lantheus buy, and AstraZeneca's blocked megamerger signal a restructuring market

Pharma M&A surges on a single day: KKR's $5.7B Integer deal, Curium's $8B Lantheus buy, and AstraZeneca's blocked megamerger signal a restructuring market

Three significant transactions occurred in the pharmaceutical and medtech sectors on August 3, highlighting a split M&A market. While mid-market buyouts such as KKR's acquisition of Integer Holdings and Curium's purchase of Lantheus proceeded, larger megamergers like AstraZeneca's faced obstacles. This suggests a trend towards restructuring within the industry.

  • 01KKR acquired Integer Holdings for $5.7 billion.
  • 02Curium purchased Lantheus in an $8 billion deal.
  • 03AstraZeneca's megamerger attempt was blocked.

Aug 3, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512